Dimerix Limited acquires USP30 inhibitor for Acute Kidney Injury
for $292m

Dimerix Limited's acquisition of MTX652 from Mission Therapeutics fills a critical gap in Dimerix’s portfolio by adding a Phase 2-ready asset focused on Acute Kidney Injury (AKI). This strategic move underscores Dimerix’s commitment to expanding its renal disease pipeline and leveraging its established expertise in kidney health. The deal, valued at up to $292 million including upfront and milestone payments, provides Mission Therapeutics with non-dilutive capital to accelerate development of MTX325, a CNS-focused asset currently in Phase 1 for Parkinson’s disease. The transaction includes double-digit tiered royalties on global net sales, aligning Dimerix's commercial success closely with the product's market performance. This financial structure incentivizes both parties to maximize MTX652's potential and ensure its rapid progression through clinical development. Guggenheim Securities acted as the exclusive financial advisor for Mission Therapeutics in this transaction. This acquisition significantly shifts competitive dynamics within the renal therapeutics space by positioning Dimerix with a broader range of kidney disease treatments, including both acute and chronic conditions. MTX652 complements Dimerix’s existing Phase 3 program in Focal Segmental Glomerulosclerosis (FSGS), thereby solidifying its position as a leading developer in renal therapeutic solutions. Post-close, the key risks include successful integration of MTX652 into Dimerix's pipeline and efficient execution of clinical trials. Additionally, navigating regulatory approvals and ensuring seamless collaboration with Mission Therapeutics will be critical for the long-term success of this initiative. The acquisition also presents growth opportunities by potentially expanding Dimerix’s market reach in AKI and leveraging synergies between MTX652 and its existing renal portfolio.